- Written informed consent
- If a woman of childbearing potential, documentation of negative pregnancy
- Histologically-confirmed head and neck squamous cell carcinoma with no evidence of
distant metastasis. The primary site may be the oral cavity, oropharynx, larynx, or
hypopharynx. Patients with squamous cell carcinoma of unknown primary, metastatic to
cervical lymph nodes, are permitted to enroll.
- High risk or intermediate risk disease, defined below. Staging evaluation should be
determined by imaging studies and complete head and neck exam in accordance with the
American Joint committee on Cancer Staging Manual, 7th edition.
o High risk patient must meet one of the following criteria:
- Surgically unresectable oral cavity. Patients who are technically resectable but
refuse surgery due to morbidity (eg. total glossectomy) are also eligible. Medically
inoperable patients are not eligible.
- Larynx: T4 any N; T2-3 and ≥ N2a
- Hypopharynx: T1-2N1-3 or T3-4N0-3
- Oropharynx: p16(-) AND T3-4 or ≥ N2a
- Unknown primary: p16(-) AND ≥ N2a
o Intermediate risk patients must meet one of the following criteria:
- Oropharynx: p16(+) AND one of the following
- T3 or ≥ N2a AND ≥ 10 pack-years tobacco exposure (see Tobacco Assessment Form,
- T4 or N3 disease irrespective of tobacco exposure
- Unknown primary: p16(+) AND one of the following
- ≥ N2a AND ≥ 10 pack-years tobacco exposure
- N3 disease irrespective of tobacco exposure
- Patients must be untreated with curative-intent surgery for current diagnosis of Stage
III, IVa, or IVb disease. Diagnostic biopsy of primary tumor and/or nodal sites is
- Diagnostic simple tonsillectomy is permitted, provided patient has
RECIST-measurable nodal disease.
- Patients with a second HNSCC primary tumor are eligible for this study, provided
more than 2 years have elapsed since the first diagnosis of HNSCC, the original
tumor was managed with surgery only (no adjuvant chemotherapy or radiotherapy),
and has not recurred.
- Patients with simultaneous primaries or bilateral tumors are excluded, with the
exception of patients with bilateral tonsil cancers or patients with T1-2, N0, M0
differentiated thyroid carcinoma (resected or management deferred), who are eligible.
- No prior systemic (chemotherapy or biologic/molecular targeted therapy) or radiation
treatment for head and neck cancer.
- Patients may have received chemotherapy or radiation for a previous, curatively
treated non-HNSCC malignancy, provided at least 2 years have elapsed.
- Patients must be untreated with radiation above the clavicles.
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
- Age ≥ 18
- Patients must have measurable disease according to RECIST 1.1
- Patients must demonstrate adequate organ function as defined.
- Sexually active patients must agree to use adequate contraceptive measures, while on
study and for 30 days after the last dose of study drug.
- Nasopharyngeal primary site
- Current participation in or previous participation in a study of an investigational
agent or using an investigational device within 4 weeks of the first dose of study
- History of severe allergic or anaphylactic reactions or hypersensitivity to
recombinant proteins or excipients in the investigational agent.
- Distant metastatic disease including CNS or leptomeningeal metastases is not allowed.
- History of immunodeficiency or is receiving systemic steroid therapy or any other form
of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
- Received prior monoclonal antibody within 4 weeks prior to study Day 1 or who has not
recovered (i.e. ≤ Grade 1 or at baseline) from adverse events due to agents
administered more than 4 weeks earlier.
- History of second malignancy within 2 years prior to Study Day 1 (except for excised
and cured non-melanoma skin cancer, carcinoma in situ of breast or cervix, superficial
bladder cancer, or T1a or T1b prostate cancer comprising < 5% of resected tissue with
normal prostate specific antigen (PSA) since resection).
- Active autoimmune disease requiring systemic treatment within the past 3 months or a
documented history of clinically severe autoimmune disease, or a syndrome that
requires systemic steroids or immunosuppressive agents.
- Known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
- Known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA
[qualitative] is detected).
- Received a live vaccine within 30 days prior to the first dose of trial treatment.
- Received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or
anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including
ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation
or checkpoint pathways).
- Significant pulmonary disease, including pulmonary hypertension, interstitial lung
disease, or active, non-infectious pneumonitis.
- History or current evidence of any other medical or psychiatric condition, therapy, or
laboratory abnormality that might confound the results of the trial, interfere with
the subject's participation for the full duration of the trial, or is not in the best
interest of the subject to participate, in the opinion of the treating investigator.
- Peripheral neuropathy ≥ Grade 2
- Significant cardiovascular disease, including:
- Cardiac failure New York Heart Association (NYHA) class III or IV.
- Myocardial infarction, severe or unstable angina within 6 months prior to Study
- History of serious arrhythmia (i.e., ventricular tachycardia, or ventricular
- Ventricular cardiac arrhythmias requiring anti-arrhythmic medications.
- Known left ventricular ejection fraction (LVEF) ≤ 50%.
- Significant thrombotic or embolic events within 3 months prior to Study Day 1.
- Major surgery within 6 weeks prior to Study Day 1 (subjects must have completely
recovered from any previous surgery prior to Study Day 1). Biopsy, diagnostic
tonsillectomy, airway tumor debulking or excisional lymph node biopsy do not
constitute major surgery.
- Active infection requiring antibiotics or antifungals within 7 days prior to first
dose of study drug.
- Significant electrolyte imbalance prior to enrollment (note that patients may be
supplemented to achieve acceptable electrolyte values):
- Hypomagnesemia <1.2 mg/dL or 0.5 mmol/L.
- Hypokalemia < 3.0 mmol/L.
- Women must not be pregnant or breastfeeding.